MaaT Pharma Announces Initiation of Coverage of its Stock by Stifel with a Buy Rating and a Target Price of EUR 16
MaaT Pharma Appoints Gianfranco Pittari, M.D. Ph.D, as Chief Medical Officer
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2024
Mustang Bio axes 81% of staffers: The CAR-T cell therapy company plans to implement a workforce reduction throughout April to preserve cash in the second quarter. Mustang had 80 full-time employees as of the end of 2023, per an SEC filing. — Ayisha Sharma
MaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies
MaaT Pharma Announces Initiation of Coverage of its Stock by Gilbert Dupont/ Groupe Société Générale
MaaT Pharma Announces 2023 Annual Results and Provides a Business Overview
MaaT Pharma Strengthens Executive Team Appointing Jonathan Chriqui as Chief Business Officer
MaaT Pharma To Present New Preclinical Data at AACR for MaaT034 Aiming To improve Patients’ Responses to Immunotherapies